BioPharmSignal logoBioPharmSignal

Biotech News

MannKind to Participate in Upcoming Investor Conferences

MannKind (MNKD)MannKindCompany update

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind’s Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Chris

Open original release

Related news

MNKDMannKind2026-02-19 14:00 EST

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

NAMSNewAmsterdam Pharma2026-05-28 12:00 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

VKTXViking Therapeutics2026-05-21 11:05 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

NAMSNewAmsterdam Pharma2026-05-11 12:41 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May

TERNTerns Pharmaceuticals2026-02-25 21:05 EST

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

ETNB89bio, Inc.2025-08-28 20:05 EST

89bio to Participate in Upcoming Investor Conferences

EMBCEmbecta2026-06-01 21:00 EST

embecta to Participate in Investor Events

MLYSMineralys Therapeutics2026-06-08 20:05 EST

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

EMBCEmbecta2026-05-08 13:00 EST

embecta to Participate at the 2026 BofA Securities Global Health Care Conference

View all latest news

MannKind

MannKind is a specialty pharmaceutical company best known for Afrezza and inhaled therapeutic delivery. The company has worked to build a broader inhaled-platform story around respiratory and diabetes care.

Recent company news

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MNKDMannKind2026-05-29 18:00 EST

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

MNKDMannKind2026-05-29 16:30 EST

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

MNKDMannKind2026-05-27 13:05 EST

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States